ECOG: The Eastern Cooperative Oncology Group

General Information
 

ECOG
  Introduction to ECOG

Clinical Trials
  Guide For Cancer Patients
  What is a clinical trial?
  Why participate?
  Does insurance cover costs?
  What if I change my mind?
  How can I join a clinical trial?
  ECOG's active protocols
 Patient Information
  Selenium E5597
  GI Studies E4203,E5202,E5204
  Melanoma E2603

  Prostate CHAARTED E3805
  Cancer in Siblings E1Y97
  Non-Hodgkins Lymphoma E4402
  Breast Cancer PACCT1: TAILORx
  Informational Videos
  Trial Summary Results

Trial Monitoring
  ECOG Data Monitoring Committee

ECOG Institutions
  Institutions by state
  Alphabetical listing
  Joining ECOG

Publications
  Publications bibliography
 
Announcements
  TAILORx Webinar Information
  NCI Press Release: Bevacizumab...
  Job Openings
  Future ECOG Meeting Dates
  Researcher Advocate Partners
  Investigator Awards
  NCI-VA Initiative

Scales and Criteria
  ECOG Performance Status
  Common Toxicity Criteria

Cancer Information
  Breast Cancer Video
  Colon Cancer Video
  Cancer Survivor Publications
  Releasing Results Guidelines

Other Cancer Sites
  ECOG Main Institutions' Sites
  Other Cooperative Groups
  Advocates/Support Groups
 

ECOG HOME PAGE

ECOG MEMBERS
INFORMATION

(password required)

GLOSSARY

SEARCH

CONTACT INFORMATION

DISCLAIMER

                    

Eastern Cooperative Oncology Group:

E2A01 Trial for Patients With Amyloidosis

You can learn more about this trial by viewing a short informational video featuring Dr. Morie Gertz, the study chair for this trial:

Click here for a list of institutions participating in this trial

Note to institutions: Use of these videos for patient education requires approval of your institution's IRB.

This trial is looking at whether Amifostine can help make transplants safer for patients with amyloidosis.

If you are placed in the study you will undergo a procedure called stem cell mobilization where cells will be collected from your bloodstream to use in the subsequent transplant. You will then receive amifostine for two days followed by melphalan and one day later your stem cells will be returned.

Patients on this study will be followed for up to ten years to assess the long-term effects of the study treatments.


You can find additional information about amyloidosis and its treatment at the following web sites:

Amyloidosis Support Network

Amyloidosis Support Groups


Information about cancer clinical trials can be found at:

National Cancer Institute Clinical Trials Information

CancerTrials Help - Coalition of Cancer Cooperative Groups